Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
ORIC Pharmaceuticals filed a notice that a shareholder plans to sell 7,000 shares of common stock through J.P. Morgan Securities LLC on Nasdaq, with an aggregate market value of $84,000. The filing lists 97,389,279 shares of common stock outstanding. The shares to be sold were acquired on 08/25/2016 by exercising stock options for cash on that same date.
Oric Pharmaceuticals director files insider transaction report for new stock options. Director Lori Anne Kunkel reported receiving a stock option covering 40,000 shares of Oric Pharmaceuticals common stock on January 2, 2026. The option has an exercise price of $8.17 per share and is held as a derivative security with direct ownership. According to the vesting terms, 1/12 of the shares subject to the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. The option is scheduled to expire on January 1, 2036, if not exercised earlier.
Oric Pharmaceuticals director Steven L. Hoerter reported a new stock option grant for 40,000 shares of common stock. The option, with an exercise price of $8.17 per share, was awarded on January 2, 2026 and is held directly. It is scheduled to vest in equal monthly installments, with 1/12 of the shares vesting on each one-month anniversary of January 2, 2026, until fully vested. The option expires on January 1, 2036, giving the director a long-dated right to purchase Oric common shares at the fixed exercise price.
Oric Pharmaceuticals, Inc. director Richard A. Heyman reported receiving a stock option grant for 40,000 shares of common stock. The option has an exercise price of $8.17 per share and expires on January 1, 2036. According to the vesting schedule, 1/12 of the shares under the option vest on each monthly anniversary of January 2, 2026, resulting in full vesting over one year. Following this grant, he beneficially owns 40,000 stock options directly.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported new equity awards. On January 2, 2026, he received a stock option covering 206,500 shares of Oric common stock with an exercise price of $8.17 per share. According to the vesting terms, 25% of these option shares vest on January 2, 2027, and the remaining shares vest in equal monthly installments over the following 36 months.
He was also granted 34,500 restricted stock units (RSUs), each representing a right to receive one share of Oric common stock. One-third of these RSUs vests on each of December 15, 2026, December 15, 2027, and December 15, 2028. Both the option and RSUs are reported as directly owned and were acquired as part of his compensation.
Oric Pharmaceuticals Chief Medical Officer Pratik S. Multani received new equity awards in the form of stock options and restricted stock units. On January 2, 2026, he was granted stock options covering 214,000 shares of Oric common stock at an exercise price of $8.17 per share. According to the vesting schedule, 25% of these options will vest on January 2, 2027, with the remaining options vesting in equal monthly installments over the following 36 months.
He was also granted 35,500 restricted stock units, each representing a contingent right to receive one share of Oric common stock. One-third of these RSUs will vest on each of December 15, 2026, December 15, 2027, and December 15, 2028, subject to the award terms. All reported holdings are listed as directly owned.
Oric Pharmaceuticals, Inc. insider equity activity shows its Chief Medical Officer reporting routine stock transactions. On December 15, 2025, the officer acquired 29,333 shares of Oric common stock at $0 through the vesting and settlement of restricted stock units (RSUs). The filing states that each RSU represents a right to receive one share of common stock.
On December 16, 2025, the officer sold 10,720 shares of common stock at a weighted average price of $9.0605 per share to cover tax withholding obligations tied to the RSU vesting, described as not a discretionary sale. After these transactions, the officer beneficially owned 68,149 shares of Oric common stock, including 2,771 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Oric Pharmaceuticals, Inc. reported insider equity activity by its Chief Financial Officer. On 12/15/2025, the CFO acquired 29,333 shares of common stock at an exercise price of $0 through the settlement of restricted stock units (RSUs), increasing direct beneficial ownership to 78,868 shares.
On 12/16/2025, the CFO sold 10,720 shares of common stock at a weighted average price of $9.0604 per share, leaving 68,148 shares owned directly. The sale was made solely to cover tax withholding obligations related to RSU vesting. The holdings include 1,218 shares acquired under the company’s 2020 Employee Stock Purchase Plan, and remaining RSUs continue to vest in equal annual installments each December 15 from 2025 through 2027.
Oric Pharmaceuticals, Inc. reported an equity transaction by its President and CEO, who is also a director. On December 15, 2025, the executive acquired 83,666 shares of common stock at $0 upon the vesting and settlement of restricted stock units (RSUs). On December 16, 2025, 33,374 shares of common stock were sold at a weighted average price of $9.06 to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary sale. Following these transactions, the executive beneficially owned 581,711 shares of Oric common stock directly, with additional RSUs remaining subject to vesting over future dates.
ORIC Pharmaceuticals, Inc. provided a program update on its enozertinib (ORIC-114) candidate, presenting recently announced data from its Phase 1b trial. The update was delivered through a presentation included as Exhibit 99.1, giving stakeholders access to the detailed clinical information the company shared on this program.